ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 257

The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis

Daphne Peelen1, Ben Zwezerijnen2, Esther Nossent1, Lilian Meijboom1, Otto Hoekstra3, Conny van der Laken4 and Alexandre Voskuyl4, 1VUmc, Amsterdam, Netherlands, 2Nuclear Medicine, VUmc, Amsterdam, Netherlands, 3Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, 4Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: interstitial lung disease, Lung Disease, positron emission tomography (PET), scleroderma and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Imaging of Rheumatic Diseases Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed and non-inflamed fibrotic tissue might help to develop treatment stratification, with the aim of improving the prognosis of (subgroups of) SSc-ILD patients. 18F-Fluoro-Dexoxyglucose Positron Emission Tomography (18F-FDG PET) scan might be a promising tool to detect inflamed lung areas, as formerly shown in a semi-quantitative setting.[1, 2] This study aims to investigate the potential role of 18F-FDG PET –scan for the quantitative assessment of metabolically active SSc related ILD.

Methods: 18F-FDG PET -scans of 22 patients with systemic auto-immune disease, including 9 with SSc , 9 with systemic lupus erythematosus (SLE) and 4 with primary Sjögren’s syndrome (pSS) , were retrospectively analyzed. FDG-uptake was quantitatively measured within 2cm-sized Regions of Interest (ROIs) at apical, medial and basal lung levels. A total of 22 ROI’s were drawn in each patient. SUVmean values of all ROI’s were corrected by the medial SUVmean bloodpool value. Subsequently, the average of 6 posterior basal SUVmean values was divided by the average of 6 posterior apical SUVmean values (basal/apical ratio). High Resolution Computed tomography (HRCT)-scans and Pulmonary Function Tests (PFT) were examined to confirm the diagnosis of ILD and to specify the pattern of fibrosis.

Results: Mean age of patients was 69.4 (SSc-ILD), 62.5(SSc without ILD), 38.9 (SLE) and, 49.3 (pSS). In SSc patients, the mean disease duration was 5.0 (SSc-ILD) and 4.4 (SSc without ILD) years. Diffuse cutaneous sclerosis was present in 2 SSc-ILD and 1 SSc without ILD patients, while other SSc patients were diagnosed with limited cutaneous SSc. ILD was present in 5 out of 9 SSc patients as confirmed by HRCT and PFT. ILD was active in 3 out of 5 SSc-ILD patients. Posterior basal/apical SUVmean ratios of SSc-ILD patients were significantly increased compared to SSc patients without ILD (p=0.016), and compared to SLE and pSS patients without ILD (p=0.001 and p=0.016, respectively), which is shown in Figure 1.

Conclusion: Our findings demonstrate that 18F-FDG PET is potentially useful for the quantitative assessment of active ILD lesions in SSc patients. The technique may therefore provide opportunities to select the patients with inflammatory regions in ILD that are most likely to respond to immunosuppression.

References:

1. Uehara, T., et al., Deep-inspiration breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease associated interstitial pneumonia. Mod Rheumatol, 2016. 26(1): p. 121-7.

2. Jacquelin, V., et al., FDG-PET/CT in the prediction of pulmonary function improvement in nonspecific interstitial pneumonia. A Pilot Study. Eur J Radiol, 2016. 85(12): p. 2200-2205.


Disclosure: D. Peelen, None; B. Zwezerijnen, None; E. Nossent, None; L. Meijboom, None; O. Hoekstra, None; C. van der Laken, None; A. Voskuyl, None.

To cite this abstract in AMA style:

Peelen D, Zwezerijnen B, Nossent E, Meijboom L, Hoekstra O, van der Laken C, Voskuyl A. The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-use-of-positron-emission-tomography-pet-scan-for-the-quantitative-assessment-of-interstitial-lung-disease-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-use-of-positron-emission-tomography-pet-scan-for-the-quantitative-assessment-of-interstitial-lung-disease-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology